CompletedNot Applicable

Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome

United States209 participantsStarted 2010-07-01

Plain-language summary

The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients and its higher sensitivity when compared to procainamide infusion (the conventional drug used in the USA). As a substudy it proposes to apply this test to early ARVC cases in order to evaluate if ECG changes similar to those seen in Brugada Syndrome could be unmasked by flecainide iv.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Suspect diagnosis of Brugada Syndrome or ARVC * Idiopathic ventricular fibrillation and suspect concealed Brugada syndrome * Family history of Brugada Syndrome * Family history of unexpected cardiac sudden death Exclusion Criteria: * Type 1 Brugada Syndrome ECG * Pregnancy * History and/or evidence of ischemic cardiomyopathy * Recent myocardial infarction * Allergy or known adverse reaction to flecainide

What they're measuring

diagnosis

Timeframe: 10 minutes

Trial details

NCT IDNCT02302274

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-07-26

View on ClinicalTrials.gov More Brugada Syndrome trials